Van Lanschot Kempen Investment Management N.V. Buys 11,539 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Van Lanschot Kempen Investment Management N.V. grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 321,514 shares of the medical research company's stock after buying an additional 11,539 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.7% of Van Lanschot Kempen Investment Management N.V.'s portfolio, making the stock its 15th largest holding. Van Lanschot Kempen Investment Management N.V. owned about 0.09% of Thermo Fisher Scientific worth $159,985,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. BI Asset Management Fondsmaeglerselskab A S grew its stake in shares of Thermo Fisher Scientific by 3.6% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 64,888 shares of the medical research company's stock valued at $32,288,000 after buying an additional 2,272 shares during the last quarter. Two Star Manager LLC grew its stake in shares of Thermo Fisher Scientific by 9.6% during the first quarter. Two Star Manager LLC now owns 21,698 shares of the medical research company's stock valued at $10,797,000 after buying an additional 1,905 shares during the last quarter. Legacy Financial Advisors Inc. grew its stake in shares of Thermo Fisher Scientific by 6.0% during the first quarter. Legacy Financial Advisors Inc. now owns 2,255 shares of the medical research company's stock valued at $1,122,000 after buying an additional 127 shares during the last quarter. Texas Capital Bank Wealth Management Services Inc grew its stake in shares of Thermo Fisher Scientific by 181.6% during the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 2,267 shares of the medical research company's stock valued at $1,128,000 after buying an additional 1,462 shares during the last quarter. Finally, Forefront Analytics LLC grew its stake in shares of Thermo Fisher Scientific by 26.9% during the first quarter. Forefront Analytics LLC now owns 524 shares of the medical research company's stock valued at $262,000 after buying an additional 111 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Stock Up 3.4%

Thermo Fisher Scientific stock traded up $16.4780 during trading hours on Friday, hitting $500.2380. 1,778,365 shares of the stock traded hands, compared to its average volume of 2,406,376. The firm's 50-day moving average price is $443.02 and its two-hundred day moving average price is $457.46. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The company has a market cap of $188.89 billion, a PE ratio of 28.93, a PEG ratio of 2.58 and a beta of 0.74. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insider Buying and Selling

In other news, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. The trade was a 1.76% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 295 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $500.04, for a total value of $147,511.80. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at approximately $57,591,606.96. This represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 18,896 shares of company stock worth $8,593,838. Insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 target price for the company in a report on Friday, July 11th. Evercore ISI dropped their target price on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Finally, Barclays increased their target price on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.